A Phase 1 Dose Escalation Study of the Tolerability, Safety, Efficacy and Pharmacokinetics of ZG006 in Patients With Small Cell Lung Cancer
Latest Information Update: 08 Aug 2025
At a glance
- Drugs Alveltamig (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions
- Sponsors Suzhou Zelgen Biopharmaceuticals
Most Recent Events
- 30 Apr 2025 Status changed from not yet recruiting to recruiting.
- 25 Sep 2024 New trial record